Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Capricor investors lost 60% to 70% after FDA briefing documents challenged the Company's claims that Deramiocel demonstrated statistically significant benefits. NEW YORK, July 29, 2026 /PRNewswire/ -- Capricor (NASDAQ: CAPR) investors were hit with a 60% to 70% drop on July 27, 2026,...